ReviewCurrent oncology reports2025
Management of Desmoid Tumors.
Review in Current oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Percutaneous Management of Desmoid Tumors.Current oncology reports · 2026Review
- Progressive Pelvic and Gluteal Desmoid Tumor in a 16-Year-Old Female: A Five-Year Multimodal Imaging Follow-Up.Cureus · 2026Article
- Experience of a Referral Center with Desmoid Tumors, Part 2: A Retrospective Analysis of 109 Cases.Cancers · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThis review highlights the evolving management of desmoid tumors, including the importance of an accurate diagnosis, the potential role for surgery and radiation therapy in select cases, growing data supporting the use of radiology-guided techniques, as well as the emerging role of systemic therapy for disease not amenable to active surveillance. RECENT
findingsThe initial management for desmoid tumors has shifted towards watchful waiting for a majority of patients. The recent FDA approval of nirogacestat, a gamma-secretase inhibitor, as well as prospective clinical trials examining multitargeted tyrosine kinase inhibitors, have increased systemic therapy options for patients. Local therapies, such as surgery, radiation and radiology-guided techniques, remain potential options in appropriate situations. An improved understanding of the underlying biology and inherent behavior of desmoid tumors has resulted in a rapidly evolving and shifting treating paradigm. A multi-disciplinary approach is critically important to provide the best outcomes for patients.
Indexed as
Identifiers
41075107What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.